Gounder MM et al. Milademetan, an oral MDM2 inhibitor, in well-differentiated/de-differentiated lipocarcoma: Phase 1 study in patients with solid tumors or lymphomas. Eur J Cancer 2023;138(2):S3-4. Abstract

Jones RL et al. Efficacy and safety findings from MANTRA: A global, randomized, multicenter, phase III study of the MDM2 inhibitor milademetan vs trabectedin in patients with dedifferentiated liposarcomas. ESMO 2023;Abstract LBA89.

LoRusso P et al. The MDM2-p53 antagonist brigimadlin (BI 907828) in patients with advanced or metastatic solid tumors: Results of a phase Ia, first-in-human, dose-escalation study. Cancer Discov 2023;13(8):1803-13. Abstract

LoRusso P et al. A phase Ia/Ib, dose-escalation/expansion study of the MDM2-p53 antagonist BI 907828 in patients with solid tumors, including advanced/metastatic liposcaroma. ASCO 2022;Abstract 11554.

Schuetze SM et al. Brightline-4: A phase III open-label, single-arm, multicentre study to assess the safety and efficacy of brigimadlin (BI 907828), an MDM2-p53 antagonist, in patients with treatment-naïve or pretreated advanced dedifferentiated liposarcoma. ESMO Sarcoma and Rare Cancers 2024;Abstract 140TiP.